← ALL REGULATORY INTELLIGENCEKNOWLEDGE / REGULATORY DEVELOPMENTS
DRAP5 November 2026 — official sourceInfant formula disclaimer directive

DRAP publishes disclaimer labelling directive for infant and young-child formula

Official directive published — text governsInfant formula disclaimer directive

DRAP published a directive on 5 November 2026 concerning mandatory disclaimer printing on labels of formula milk products intended for children aged 1–36 months.

DRAP published a directive on 5 November 2026 concerning mandatory disclaimer printing on labels of formula milk products intended for children aged 1–36 months.

01 / REGULATORY ANALYSIS

The directive's stated subject

The Drug Regulatory Authority of Pakistan posted a regulatory directive dated 5 November 2026 concerning mandatory printing of a disclaimer on formula-milk labels intended for infants and young children aged 1 to 36 months. The official posting provides a downloadable underlying instrument.

The public listing verifies the subject of the instrument, but the full legally required wording, any exemptions, applicable transition period and implementation date must be obtained from the attached directive. Those specifics should not be inferred from its title.

02 / REGULATORY ANALYSIS

Who should assess the notice

Manufacturers, importers, authorised distributors, brand owners and businesses responsible for formula product labels should compare their packaging against the original signed instrument. The impact may differ based on product approvals and the categories expressly identified in the directive.

Any associated advertising, safety or packaging implications must be checked against the actual requirements rather than assumed to follow automatically.

03 / REGULATORY ANALYSIS

Compliance workstream

Retrieve the official attachment, record the scope and exact label text, establish how any approved labels may need to be changed, and document the effective date before ordering replacement packaging. Suppliers should reconcile artwork instructions with regulatory approvals and supply-chain commitments.

Existing stocks, import shipments and distribution notices should not be reclassified solely on the basis of this short public announcement.

04 / REGULATORY ANALYSIS

What remains unconfirmed

This briefing deliberately does not reproduce or invent the disclaimer sentence, a grace period, a penalty or an exemption. The downloadable primary document must be read before giving product-specific implementation advice.

Related reading

For other notices, decisions and regulatory developments, see the Regulatory Intelligence archive. This report does not treat a proposed measure or operational notice as enacted law.

OFFICIAL SOURCEInfant formula disclaimer directive

Drug Regulatory Authority of Pakistan — 5 November 2026

READ SOURCE ↗